- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04027361
Amphetamine Extended Release Tablets and Driving Performance in Subjects With Attention Deficit/Hyperactivity Disorder (ADHD)
Driving Performance in Patients Aged 18 to 25 Years With Attention-Deficit/Hyperactivity Disorder (ADHD) After a Single-Dose of Amphetamine Extended-Release Tablets: A Pilot, Double-Blind, Placebo-Controlled Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
At a single US-based study site, a driving simulation will be used to assess the effect on driving performance for the co-primary endpoints, study subjects' driving performance at 45 minutes and 10 hours post-dose, compared with placebo. Eligible subjects will be prescreened for ADHD but otherwise healthy, aged 18-25 years.
Driving simulations that simulate common driving events to which the study subject must react. The reactions to each event will be assessed. Using a parallel-group design, subjects will be assessed while on study drug, and while on placebo.
Safety assessments will include spontaneously reported treatment-emergent adverse events and vital signs at 4 hours post-dose.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males or females aged 18 to 25 years, inclusive, at the time of screening who have a valid driver's license.
- Normal visual acuity (either uncorrected or corrected with glasses, contact lenses or surgery) at Screening based upon clinical assessment of the Investigator
- Diagnosed with ADHD using the Diagnostic and Statistical Manual of Mental Disorders Version 5 (DSM-5) criteria based on ADHD module from the Mini-International Neuropsychiatric Interview (M.I.N.I) version 7.0.2.
- IQ within normal range based upon clinical assessment of the Investigator.
- For female participants, presently using an acceptable method of contraception based upon clinical assessment of the Investigator.
- Willing to abstain from using any forms of cannabinoids (THC, CBD, hemp oil, etc.) for 2 weeks prior to the Driving Simulation Visit (if applicable).
- Be able to understand, read, write, and speak English fluently to complete the study related materials.
- Be informed of the nature of the study and give written consent prior to any study procedure.
Exclusion Criteria:
- Current or lifetime history of bipolar disorder or any psychotic disorder.
- Current active symptoms of major depression generalized anxiety disorder, obsessive-compulsive disorder, panic disorder, or post-traumatic stress disorder based upon clinical assessment of the Investigator.
- Known history of chronic medical illnesses including known structural cardiac disorders, serious cardiac conditions, serious arrhythmias, cardiomyopathy, and known family history of sudden death.
- History of uncontrolled hypertension or a resting systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg. Patients with well-controlled hypertension on a stable dose for at least 3 months of anti-hypertensives will be allowed to participate.
Have clinically significant findings in vital signs measurements at Screening including:
- Systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg (average of triplicate measurements)
- Heart rate >100 bpm (average of triplicate measurements)
- Known history or presence of significant renal or hepatic disease.
- Use of monoamine oxidase inhibitors (MAOI), e.g. selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue, within 14 days of the Driving Simulator Visit.
- Use of ADHD medications including all stimulants (methylphenidate, amphetamine or derivatives of any of these products), within 48 hours of the Driving Simulator Visit.
- Participation in a clinical study in which an investigational drug was administered within 30 days prior to Screening.
- Known history of allergy/hypersensitivity to amphetamine or any of the components of the test products.
- Known history of lack of clinical response to amphetamine based upon Investigator assessment
- Any uncontrolled medical condition that, in the opinion of Medical Monitor or Sponsor, would preclude study participation.
- History or presence of alcohol dependence or substance abuse disorder or within the last 6 months based upon clinical assessment of the Investigator.
- Positive urine pregnancy test at Driving Simulator Visit
- Positive breath alcohol test at Driving Simulator Visit.
- Patient's inability or unwillingness to follow directions from the study research staff.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Amphetamine ER Tablets, 20 mg
Double-blind amphetamine extended-release tablets, 20 mg dose, single tablet, administered at baseline
|
A single 20 mg dose of amphetamine ER Tablet, orally administered
Other Names:
|
Placebo Comparator: Placebo
Matching double-blind placebo tablets, 20 mg dose, single tablet, administered at baseline
|
A single 20 mg dose of amphetamine ER Tablet, orally administered
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Composite Reaction Time Score
Time Frame: Measured at pre-dose, 45 minutes and 3 hours post-dose
|
Measurement of reaction time across a series of driving simulations
|
Measured at pre-dose, 45 minutes and 3 hours post-dose
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Attention Deficit and Disruptive Behavior Disorders
- Neurodevelopmental Disorders
- Attention Deficit Disorder with Hyperactivity
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Dopamine Agents
- Dopamine Uptake Inhibitors
- Central Nervous System Stimulants
- Sympathomimetics
- Adrenergic Uptake Inhibitors
- Amphetamine
Other Study ID Numbers
- TRI108-ADD-600
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on ADHD
-
The Hong Kong Polytechnic UniversityRecruiting
-
VIZO Specs LtdRecruiting
-
University of North Carolina, Chapel HillNational Institute of Mental Health (NIMH)Recruiting
-
Loewenstein HospitalWingate InstituteRecruiting
-
Florida State UniversityRecruiting
-
Florida International UniversityRecruiting
-
Region Örebro CountyRecruiting
-
Johns Hopkins UniversityWithdrawn
-
Tris Pharma, Inc.Premier Research Group plcCompleted
Clinical Trials on Amphetamine Extended Release (ER) Tablet 20 mg
-
Zogenix, Inc.Completed
-
Tris Pharma, Inc.Premier Research Group plcCompleted
-
TaiRx, Inc.CompletedAdvanced CancerTaiwan
-
AstraZenecaWithdrawnHealthy Male Subjects | Pharmacokinetics | Safety | Food EffectUnited Kingdom
-
Boehringer IngelheimCompleted
-
GlaxoSmithKlineTerminated
-
Ultragenyx Pharmaceutical IncCompletedHereditary Inclusion Body Myopathy (HIBM)United States
-
Hangzhou Highlightll Pharmaceutical Co., LtdCompleted
-
Zogenix, Inc.Completed
-
Ultragenyx Pharmaceutical IncCompletedHereditary Inclusion Body Myopathy | GNE MyopathyUnited States, Israel